Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's disease. The data also showed 88% of patients achieved corticosteroid-free remission for 90 days, with a consistent safety profile over the long term. These results highlight TREMFYA's potential as a long-term treatment option for sustained disease control in Crohn's disease, a chronic condition with no cure. Further data will continue to be collected through a five-year extension period.
Johnson & Johnson's stock trades at USD 264.37 on Pluang as of Oct 13, 2026 03:02 WIB, nearing its 52-week high of USD 278.43 and well above the 52-week low of USD 186.00. The stock gained 1.12% in the last day, contrasting with a predominantly sell order activity of 84% on the platform. This performance highlights investor interest in JNJ despite the cautious trading sentiment seen on Pluang.
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
As of October 2026, U.S. Treasury bills yield between 3.98% and 4.44% depending on maturity, surpassing Johnson & Johnson's 2.05% dividend yield. Treasury bills guarantee fixed returns until maturity but carry reinvestment and inflation risks, while ...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
